| Recruiting | A Study of GEN1106 in Participants With Solid Tumors Solid Tumors, Urothelial Carcinoma | Phase 1 | 2026-04-14 |
| Recruiting | Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maint Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC | Phase 3 | 2026-04-03 |
| Recruiting | First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-r R/R AML, R/R HR-MDS, Acute Myeloid Leukemia | Phase 1 | 2026-02-16 |
| Recruiting | Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2026-02-01 |
| Recruiting | Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer Non-small Cell Lung Cancer (NSCLC) | Phase 2 | 2026-01-30 |
| Recruiting | Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participan Endometrial Cancer, Recurrent or Progressive Endometrial Cancer | Phase 3 | 2025-11-28 |
| Active Not Recruiting | Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma o Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV) | Phase 2 | 2025-07-25 |
| Active Not Recruiting | Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Pla Platinum-resistant Ovarian Cancer | Phase 3 | 2025-02-07 |
| Terminated | A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors Malignant Solid Tumor | Phase 1 / Phase 2 | 2025-01-29 |
| Active Not Recruiting | Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | Phase 3 | 2024-11-25 |
| Terminated | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 / Phase 2 | 2024-11-13 |
| Recruiting | Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors Advanced Malignant Solid Tumors, Metastatic Malignant Solid Tumors | Phase 1 | 2024-08-28 |
| Active Not Recruiting | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) I Diffuse Large B-Cell Lymphoma | Phase 3 | 2024-08-13 |
| Terminated | Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Malignant Solid Tumor | Phase 1 / Phase 2 | 2024-05-14 |
| Recruiting | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Asse Follicular Lymphoma (FL) | Phase 3 | 2024-02-05 |
| Terminated | PRO1107 in Patients With Advanced Solid Tumors Endometrial Cancer, Ovarian Cancer, Triple Negative Breast Cancer | Phase 1 / Phase 2 | 2024-01-03 |
| Active Not Recruiting | A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors Malignant Solid Tumor | Phase 1 | 2023-11-24 |
| Withdrawn | GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer Advanced Endometrial Cancer | Phase 2 | 2023-10-01 |
| Terminated | A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | 2023-09-21 |
| Terminated | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | 2023-03-15 |
| Terminated | A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects Wi Non-CNS Tumor | Phase 1 / Phase 2 | 2023-03-08 |
| Active Not Recruiting | Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma Diffuse Large B-Cell Lymphoma | Phase 2 | 2023-03-06 |
| Active Not Recruiting | A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Diffuse Large B-Cell Lymphoma | Phase 3 | 2023-02-08 |
| Recruiting | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1 / Phase 2 | 2022-12-07 |
| Completed | Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors Solid Tumor, Adult | Phase 1 | 2022-10-24 |
| Active Not Recruiting | A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B- Diffuse Large B-Cell Lymphoma | Phase 3 | 2022-10-08 |
| Active Not Recruiting | Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between th Non-hodgkin Lymphoma | Phase 1 | 2022-10-04 |
| Terminated | A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tu Solid Tumor, Adult | Phase 1 / Phase 2 | 2022-10-04 |
| Active Not Recruiting | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Asse Follicular Lymphoma (FL) | Phase 3 | 2022-09-20 |
| Active Not Recruiting | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma | Phase 2 | 2022-08-17 |
| Recruiting | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combinat Non-Hodgkin Lymphoma | Phase 2 | 2022-06-14 |
| Active Not Recruiting | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monother B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | 2022-03-10 |
| Terminated | GEN1047 for Solid Tumors - First in Human (FIH) Trial Breast Cancer, Breast Neoplasms, Endometrial Cancer, Endometrial Neoplasm, Ovarian Cancer, Ovarian Neoplasms | Phase 1 / Phase 2 | 2021-12-13 |
| Active Not Recruiting | Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of R Non Small Cell Lung Cancer Metastatic | Phase 2 | 2021-10-27 |
| Completed | GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies Solid Tumor | Phase 1 | 2021-06-15 |
| Terminated | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | 2021-03-09 |
| Active Not Recruiting | A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Larg Diffuse Large B-cell Lymphoma | Phase 3 | 2021-01-13 |
| Active Not Recruiting | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome | Phase 1 / Phase 2 | 2020-11-25 |
| Active Not Recruiting | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | 2020-11-03 |
| Active Not Recruiting | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma | Phase 1 / Phase 2 | 2020-08-20 |
| Terminated | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer | Phase 1 / Phase 2 | 2020-07-15 |
| Terminated | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma | Phase 1 / Phase 2 | 2020-03-13 |
| Active Not Recruiting | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Phase 1 / Phase 2 | 2019-09-17 |
| Active Not Recruiting | GEN1046 Safety Trial in Patients With Malignant Solid Tumors Solid Tumors | Phase 1 / Phase 2 | 2019-05-14 |
| Completed | A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies Solid Tumor | Phase 1 / Phase 2 | 2019-02-27 |
| Active Not Recruiting | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Phase 1 / Phase 2 | 2018-06-26 |
| Terminated | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors Colorectal Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer | Phase 1 / Phase 2 | 2018-04-30 |
| Completed | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors Ovarian Cancer, Cervical Cancer, Endometrial Cancer | Phase 1 / Phase 2 | 2016-11-23 |
| Completed | Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN) Head and Neck Cancer | Phase 1 / Phase 2 | 2010-03-01 |
| Terminated | Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Ch Head and Neck Cancer, Squamous Cell Carcinoma | Phase 1 / Phase 2 | 2008-09-01 |
| Terminated | Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer Colorectal Cancer | Phase 1 / Phase 2 | 2008-04-01 |
| Completed | Zalutumumab in Non-curable Patients With SCCHN Head and Neck Cancer, Squamous Cell Cancer | Phase 2 | 2008-01-01 |
| Terminated | Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer Non Small Cell Lung Cancer | Phase 2 | 2007-04-01 |
| Terminated | Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer Head and Neck Cancer, Squamous Cell Cancer | Phase 1 / Phase 2 | 2006-12-01 |
| Completed | Zalutumumab in Patients With Non-curable Head and Neck Cancer Head and Neck Cancer, Squamous Cell Cancer | Phase 3 | 2006-11-01 |
| Completed | Zalutumumab in Head and Neck Cancer Head and Neck Neoplasms | Phase 1 / Phase 2 | 2003-12-01 |
| Completed | Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin. Cutaneous T-Cell Lymphoma | Phase 2 | 2003-05-27 |
| Completed | Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin. Cutaneous T-Cell Lymphoma | Phase 2 | 2003-04-30 |
| Terminated | Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) Rheumatoid Arthritis | Phase 2 / Phase 3 | 2002-03-04 |
| Approved For Marketing | Expanded Access Program for Epcoritamab Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL) | — | — |
| Withdrawn | Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors Non-small Cell Lung Cancer | Phase 2 | — |